UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 125

Sortiert nach

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

Journal of thoracic oncology, 2021-09, Vol.16 (9), p.1501-1511

2021

Link zum Volltext

Verfügbarkeit prüfen

Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial

Journal of clinical oncology, 2013-09, Vol.31 (26), p.3219-3225

2013

Link zum Volltext

Verfügbarkeit prüfen

A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: a large population-based study

BMC cancer, 2021-05, Vol.21 (1), p.1-640, Article 640

2021

Link zum Volltext

Verfügbarkeit prüfen

Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study

Journal of hematology and oncology, 2017-09, Vol.10 (1), p.153-153, Article 153

2017

Link zum Volltext

Verfügbarkeit prüfen

Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment

Cancer biology & medicine, 2018-11, Vol.15 (4), p.443-451

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of immunotherapy in KRAS -mutant advanced NSCLC: A real-world study in a Chinese population

Frontiers in oncology, 2023-01, Vol.12, p.1070761-1070761

2023

Link zum Volltext

Verfügbarkeit prüfen

Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review

Thoracic cancer, 2020-10, Vol.11 (10), p.3001-3006

2020

Link zum Volltext

Verfügbarkeit prüfen

Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303

Thoracic cancer, 2019-03, Vol.10 (3), p.551-556

2019

Link zum Volltext

Verfügbarkeit prüfen

Relationship between tumor size and metastatic site in patients with stage IV non-small cell lung cancer: A large SEER-based study

PeerJ (San Francisco, CA), 2019-10, Vol.7, p.e7822-e7822, Article e7822

2019

Link zum Volltext

Verfügbarkeit prüfen

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial

Cancer medicine (Malden, MA), 2020-04, Vol.9 (8), p.2621-2630

2020

Link zum Volltext

Verfügbarkeit prüfen

Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody

Journal for immunotherapy of cancer, 2023-02, Vol.11 (2), p.e006234

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial

Signal transduction and targeted therapy, 2022-01, Vol.7 (1), p.25-25, Article 25

2022

Link zum Volltext

Verfügbarkeit prüfen

Chinese Experts Consensus on Immune Checkpoint Inhibitors  for Non-small Cell Lung Cancer (2020 Version)

Zhongguo fei ai za zhi, 2021-04, Vol.24 (4), p.217-235

2021

Link zum Volltext

Verfügbarkeit prüfen

SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer

Journal for immunotherapy of cancer, 2023-02, Vol.11 (2), p.e006055

2023

Link zum Volltext

Verfügbarkeit prüfen

Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial

Journal for immunotherapy of cancer, 2022-12, Vol.10 (12), p.e004952

2022

Link zum Volltext

Verfügbarkeit prüfen

Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)

Zhongguo fei ai za zhi, 2020-02, Vol.23 (2), p.65-76

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis

Drug design, development and therapy, 2016-01, Vol.10 (Issue 1), p.1961-1972

2016

Link zum Volltext

Verfügbarkeit prüfen

The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study

Translational lung cancer research, 2022-05, Vol.11 (5), p.776-785

2022

Link zum Volltext

Verfügbarkeit prüfen

Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)

Journal of the National Cancer Center, 2023-12, Vol.3 (4), p.256-265

2023

Link zum Volltext

Verfügbarkeit prüfen

Occurrence of hypertension during third‐line anlotinib is associated with progression‐free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial

Thoracic cancer, 2021-09, Vol.12 (17), p.2345-2351

2021

Link zum Volltext

Verfügbarkeit prüfen

Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese

BMC cancer, 2010-08, Vol.10 (1), p.456-456, Article 456

2010

Link zum Volltext

Verfügbarkeit prüfen

Cutaneous metastasis from pancreatic cancer: A case report and systematic review of the literature

Oncology letters, 2014-12, Vol.8 (6), p.2654-2660

2014

Link zum Volltext

Verfügbarkeit prüfen

Real-world data of anlotinib for gastrointestinal tumors with liver metastases in China

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.738-738

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 125

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(112)
Mit Volltextzugriff
(123)

Publikationsform

Artikel
(124)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(90)
Life Sciences & Biomedicine
(80)
Oncology
(65)
Humans
(48)
Lung Cancer
(37)
Chemotherapy
(36)
Cancer Therapies
(27)
Patients
(26)
Cancer
(24)
Female
(24)
Lung Neoplasms - Drug Therapy
(23)
Male
(22)
Metastasis
(22)
Middle Aged
(22)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(21)
Adult
(20)
Immunotherapy
(20)
Medical Prognosis
(20)
Prognosis
(20)
Aged
(19)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial

A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: a large population-based study

Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study

Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)

Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment

Efficacy of immunotherapy in KRAS -mutant advanced NSCLC: A real-world study in a Chinese population

Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review

Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303

Relationship between tumor size and metastatic site in patients with stage IV non-small cell lung cancer: A large SEER-based study

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial

Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody

Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial

Chinese Experts Consensus on Immune Checkpoint Inhibitors  for Non-small Cell Lung Cancer (2020 Version)

SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer

Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial

Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)

Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis

Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy

The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study

Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)

Occurrence of hypertension during third‐line anlotinib is associated with progression‐free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial

Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese

Cutaneous metastasis from pancreatic cancer: A case report and systematic review of the literature

Real-world data of anlotinib for gastrointestinal tumors with liver metastases in China

Suchergebnisse filtern